Zr-DFO-VRC-HIVMAB060-00-AB
Phase 1Small molecule
Zr-DFO-VRC-HIVMAB060-00-AB is one of 4 small molecule programs targeting Monoclonal. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Monoclonal
#DrugCompanyPhaseTrials
1Libtayo
RegeneronPhase 2
Rabies Vaccine
NovartisPhase 2
Human Rabies Immunoglobulin(hrig)
GGenrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
Zr-DFO-VRC-HIVMAB060-00-AB
UUniversity of California, San Francisco
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zr-DFO-VRC-HIVMAB060-00-AB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details